^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + trastuzumab imbotolimod (BDC-1001) (HER2 inhibitor, TLR8 agonist, TLR7 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
657MO - Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
Published date:
10/16/2023
Excerpt:
Our novel ISAC BDC-1001 (mono/combo) led to tolerable, encouraging efficacy, translational biomarker data consistent with novel MOA in pts with pretreated HER2+ tumors, particularly at the 20mg/kg q2w RP2D.
Trial ID:
Source:
Title:
A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.
Published date:
05/25/2023
Excerpt:
...BDC-1001 in patients with advanced HER2-expressing solid tumors....Antitumor activity was observed at a range of doses and malignancies....BDC-1001 mono and combo were well-tolerated. Targeted serum exposure levels were achieved, and encouraging clinical activity was noted in heavily pretreated pts with various HER2 positive tumors, especially in the 20 mg/kg q2w cohorts.
DOI:
10.1200/JCO.2023.41.16_suppl.2538
Trial ID:
